Evidence map›Paper›PMID 42121263›Full record

ReviewJournal of translational medicine2026

Metabolic pattern changes of macrophages during cancer development and progression.

Guanfu Liu, Binxue Wang, Shaojie Wang, Shi Li, Hua Han, Tai An

Abstract readReview
In one paragraph

Review in Journal of translational medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Guanfu Liu *Institute of Future Agriculture, Northwest A&F University, Yangling, 712100, China.
Binxue Wang *Institute of Future Agriculture, Northwest A&F University, Yangling, 712100, China.
Shaojie WangInstitute of Future Agriculture, Northwest A&F University, Yangling, 712100, China.
Shi LiInstitute of Future Agriculture, Northwest A&F University, Yangling, 712100, China.
Hua HanInstitute of Future Agriculture, Northwest A&F University, Yangling, 712100, China. huahan@fmmu.edu.cn.
Tai AnInstitute of Future Agriculture, Northwest A&F University, Yangling, 712100, China. antai008@nwafu.edu.cn.ORCID 0009-0003-7311-4340

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundTumor-associated macrophages (TAMs) are critical components of the immune cell population within the tumor microenvironment (TME), where they play dynamic and multifaceted roles throughout the progression of tumorigenesis. Recent evidence suggests that shifts in macrophage metabolic programs-including glycolysis, oxidative phosphorylation, fatty acid utilization, glutamine metabolism, and the pentose phosphate pathway, are closely associated with diverse and context-dependent functional states rather than fixed polarization phenotypes. During tumor progression toward invasion and metastasis, macrophage metabolic programs dynamically adapt to spatial and temporal variations within the TME, often contributing to immunoregulatory or tumor-supportive niches that facilitate angiogenesis, tumor dissemination, immune evasion, and metabolic crosstalk with tumor cells. However, the precise mechanisms underlying these context-dependent adaptations remain incompletely understood. MAIN BODY: This article reviews current evidence regarding TAM activation states and metabolic reprogramming by various signals in the TME during tumorigenesis and tumor progression, as well as dynamic alterations in TAM metabolic patterns. Furthermore, we explore how secondary metabolites present in the TME influence macrophage metabolic reprogramming and summarize current research on potential therapeutic agents targeting macrophage metabolism.

conclusionsWe propose that modulating key metabolic regulators in TAMs or intervening in metabolic-immune crosstalk pathways may offer novel strategies for precision medicine in cancer therapy, providing a theoretical foundation for metabolic intervention-based immunotherapeutic approaches.

Indexed as

CarcinogenesisDisease ProgressionMacrophagesNeoplasmsAnimalsHumansMetabolic ReprogrammingTumor-Associated MacrophagesTumor MicroenvironmentCancer immunotherapyImmunometabolismMetabolic intermediatesMetabolic reprogrammingTumor-associated macrophagesTumor microenvironment

Identifiers

PMID42121263
PMCPMC13339408

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.